{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:03:46Z","timestamp":1791644626689,"version":"4.3.4"},"reference-count":29,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ARM"],"abstract":"<jats:p>Background: Several studies focused on the importance of managing small airways disease in the treatment of severe asthma, whose improvement can improve respiratory symptoms, lung function, and airways inflammation, potentially reaching the objective of clinical remission. Methods: Twenty-five patients with severe asthma and without bronchiectasis were enrolled. They were started on biological therapies with Omalizumab, Dupilumab, Benralizumab or Mepolizumab. Follow-up evaluations were conducted at baseline (T0) and after one year of biological therapy (T1). Assessments included clinical evaluations, spirometry, questionnaires, and inflammatory markers. Results: Predictive analysis identified baseline FeNO 350 mL\/s levels as a significant predictor of clinical remission in both univariable and multivariable analysis. Higher FeNO 350 mL\/s levels at T0 were associated with an increased likelihood of achieving remission (p = 0.012). The optimal cutoff value for FeNO 350 mL\/s was determined to be 18 ppb, based on the Younden Index. Conclusions: Following patients with severe asthma on biological therapy for one year, FeNO 350 mL\/s could be used as a predictive factor of clinical remission, highlighting its importance as inflammatory marker not only in small airways disease, but also in predicting clinical remission in severe asthmatic patients.<\/jats:p>","DOI":"10.3390\/arm93050037","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T13:03:02Z","timestamp":1758114182000},"page":"37","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["FeNO 350 mL\/s: Unlocking the Small Airways to Achieve Clinical Remission in Severe Asthma\u2014A Pilot Study"],"prefix":"10.3390","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9920-780X","authenticated-orcid":false,"given":"Vitaliano Nicola","family":"Quaranta","sequence":"first","affiliation":[{"name":"Institute of Respiratory Disease, University of Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6127-2486","authenticated-orcid":false,"given":"Andrea","family":"Portacci","sequence":"additional","affiliation":[{"name":"Institute of Respiratory Disease, University of Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Maselli","sequence":"additional","affiliation":[{"name":"Institute of Respiratory Disease, University of Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Tornesello","sequence":"additional","affiliation":[{"name":"Institute of Respiratory Disease, University of Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Granito","sequence":"additional","affiliation":[{"name":"Institute of Respiratory Disease, University of Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Rociola","sequence":"additional","affiliation":[{"name":"Institute of Respiratory Disease, University of Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1563-6864","authenticated-orcid":false,"given":"Silvano","family":"Dragonieri","sequence":"additional","affiliation":[{"name":"Institute of Respiratory Disease, University of Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna Elisiana","family":"Carpagnano","sequence":"additional","affiliation":[{"name":"Institute of Respiratory Disease, University of Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40733-016-0029-3","article-title":"Asthma costs and social impact","volume":"3","author":"Nunes","year":"2017","journal-title":"Asthma Res. Pr."},{"key":"ref_2","unstructured":"(2023, October 22). Global Initiative for Asthma. Available online: www.ginasthma.org."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S2213-2600(19)30049-9","article-title":"Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): Baseline data from a prospective cohort study","volume":"7","author":"Postma","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/978-3-642-23274-9_14","article-title":"Muscarinic receptor antagonists: Effects on pulmonary function","volume":"208","author":"Buels","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12948-021-00147-8","article-title":"Small airway dysfunction and poor asthma control: A dangerous liaison","volume":"19","author":"Cottini","year":"2021","journal-title":"Clin. Mol. Allergy."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1016\/j.jaip.2023.07.041","article-title":"Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus","volume":"11","author":"Canonica","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pr."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"McDowell, P.J., McDowell, R., Busby, J., Eastwood, M.C., Patel, P.H., Jackson, D.J., Mansur, A., Patel, M., Burhan, H., and Doe, S. (2023). Clinical remission in severe asthma with biologic therapy: An analysis from the UK Severe Asthma Registry. Eur. Respir. J., 62.","DOI":"10.1183\/13993003.00819-2023"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.chest.2023.10.046","article-title":"Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies","volume":"165","author":"Hansen","year":"2024","journal-title":"Chest"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Carpagnano, G.E., Portacci, A., Nolasco, S., Detoraki, A., Vatrella, A., Calabrese, C., Pelaia, C., Montagnolo, F., Scioscia, G., and Valenti, G. (2024). Features of severe asthma response to anti-IL5\/IL5r therapies: Identikit of clinical remission. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1343362"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4104\/pcrj.2009.00010","article-title":"The Asthma Control Test (ACT) as a predictor of GINA guideline-defined asthma control: Analysis of a multinational cross-sectional survey","volume":"18","author":"Thomas","year":"2009","journal-title":"Prim. Care Respir. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1089\/jamp.2015.1212","article-title":"Validation of the \u2018Test of the Adherence to Inhalers\u2019 (TAI) for Asthma and COPD Patients","volume":"29","author":"Plaza","year":"2016","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jaci.2012.08.023","article-title":"The Asthma Control Test and Asthma Control Questionnaire for assessing asthma control: Systematic review and meta-analysis","volume":"131","author":"Jia","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur. Respir. J."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Horv\u00e1th, I., Barnes, P.J., Loukides, S., Sterk, P.J., H\u00f6gman, M., Olin, A.-C., Amann, A., Antus, B., Baraldi, E., and Bikov, A. (2017). A European Respiratory Society technical standard: Exhaled biomarkers in lung disease. Eur. Respir. J., 49.","DOI":"10.1183\/13993003.00965-2016"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","article-title":"An official ATS clinical practice guideline: Interpretation of exhaled nitric oxide levels (FENO) for clinical applications","volume":"184","author":"Dweik","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.arbres.2022.05.007","article-title":"Predicting Bronchial Hyperresponsiveness in Patients with Asthma: The Role of Impulse Oscillometry","volume":"58","author":"Katsoulis","year":"2022","journal-title":"Arch. Bronconeumol. (Ed. Impr.)"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1900753","DOI":"10.1183\/13993003.00753-2019","article-title":"Technical standards for respiratory oscillometry","volume":"55","author":"King","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_18","unstructured":"Italian Medicines Agency (AIFA) (2025, January 01). Criteria for Prescribing Biologic Therapies in Severe Asthma, Available online: https:\/\/www.aifa.gov.it."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00408-022-00579-2","article-title":"Impact of Biologic Therapy on the Small Airways Asthma Phenotype","volume":"200","author":"Chan","year":"2022","journal-title":"Lung"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40413-017-0153-4","article-title":"Small airways disease and severe asthma","volume":"10","author":"Carr","year":"2017","journal-title":"World Allergy Organ. J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S2213-2600(14)70103-1","article-title":"Unlocking the quiet zone: The small airway asthma phenotype","volume":"2","author":"Lipworth","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.rmed.2016.05.006","article-title":"The prevalence of small airways disease in adult asthma: A systematic literature review","volume":"116","author":"Usmani","year":"2016","journal-title":"Respir. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"183","DOI":"10.5603\/ARM.a2022.0015","article-title":"The levels and correlations of FeNO, blood eosinophils and lung function in well-controlled asthma","volume":"90","author":"Nakwan","year":"2022","journal-title":"Adv. Respir. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1073\/pnas.051629498","article-title":"NO chemical events in the human airway during the immediate and late antigen-induced asthmatic response","volume":"98","author":"Dweik","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.2174\/1389450119666180212120012","article-title":"Blood Eosinophils as Biomarkers to Drive Treatment Choices in Asthma and COPD","volume":"19","author":"Kostikas","year":"2018","journal-title":"Curr. Drug Targets"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/thoraxjnl-2018-211540","article-title":"Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): A systematic review and meta-analysis","volume":"73","author":"Petsky","year":"2018","journal-title":"Thorax"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1080\/02770903.2024.2370012","article-title":"Evaluation of multiple-flows exhaled nitric oxide and its clinical significance in severe asthmatic patients treated with biologics: A prospective real-life study","volume":"61","author":"Pianigiani","year":"2024","journal-title":"J. Asthma"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Abdo, M., Watz, H., Veith, V., Kirsten, A.-M., Biller, H., Pedersen, F., von Mutius, E., Kopp, M.V., Hansen, G., and Waschki, B. (2020). Small airway dysfunction as predictor and marker for clinical response to biological therapy in severe eosinophilic asthma: A longitudinal observational study. Respir. Res., 21.","DOI":"10.1186\/s12931-020-01543-5"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Chan, R., and Lipworth, B.J. (2023). Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma. BMJ Open Respir. Res., 10.","DOI":"10.1136\/bmjresp-2022-001472"}],"container-title":["Advances in Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2543-6031\/93\/5\/37\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:47:07Z","timestamp":1760035627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2543-6031\/93\/5\/37"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["arm93050037"],"URL":"https:\/\/doi.org\/10.3390\/arm93050037","relation":{},"ISSN":["2543-6031"],"issn-type":[{"value":"2543-6031","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]}}}